MedPath

Galderma Group AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$22.9B
Website
http://www.galderma.com/

Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

Not Applicable
Active, not recruiting
Conditions
Chin Augmentation
Chin Retrusion
Interventions
Device: Restylane Lyft with Lidocaine
Device: Juvederm Voluma XC
First Posted Date
2023-03-21
Last Posted Date
2024-05-09
Lead Sponsor
Galderma R&D
Target Recruit Count
174
Registration Number
NCT05777759
Locations
🇺🇸

United States, California, Manhattan Beach, California, United States

🇵🇷

Galderma Research Site, San Juan, Puerto Rico

Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing

Not Applicable
Active, not recruiting
Conditions
Temporal Hollowing
Interventions
Device: Restylane Contour
First Posted Date
2023-01-20
Last Posted Date
2024-05-03
Lead Sponsor
Galderma R&D
Target Recruit Count
225
Registration Number
NCT05691972
Locations
🇺🇸

Galderma Research Site, Nashville, Tennessee, United States

Healing Ointment Usage Post-surgical Procedure

Phase 4
Completed
Conditions
Surgical Wound
Interventions
Drug: Cetaphil Healing Ointment
First Posted Date
2023-01-17
Last Posted Date
2023-01-17
Lead Sponsor
Galderma R&D
Target Recruit Count
15
Registration Number
NCT05686928
Locations
🇺🇸

Legacy Dermatology, Frisco, Texas, United States

🇺🇸

Derm Texas, Dallas, Texas, United States

Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition

Not Applicable
Completed
Conditions
Jawline Definition
Interventions
Device: Restylane Lyft Lidocaine
First Posted Date
2022-11-21
Last Posted Date
2024-06-25
Lead Sponsor
Galderma R&D
Target Recruit Count
140
Registration Number
NCT05622812
Locations
🇨🇦

Galderma Research Site, Westmount, Quebec, Canada

Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers

Not Applicable
Completed
Conditions
Volume Deficiency of the Midface
Interventions
Device: Juvederm Voluma
Device: Restylane Contour
First Posted Date
2022-11-21
Last Posted Date
2024-03-22
Lead Sponsor
Galderma R&D
Target Recruit Count
11
Registration Number
NCT05622851
Locations
🇺🇸

The Aesthetic Clinique, Santa Rosa Beach, Florida, United States

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler

Not Applicable
Completed
Conditions
Gene Expression
Interventions
Device: Sculptra
Device: Radiesse Plus
First Posted Date
2022-11-17
Last Posted Date
2024-03-22
Lead Sponsor
Galderma R&D
Target Recruit Count
21
Registration Number
NCT05620043
Locations
🇺🇸

Miami Dermatology & Laser Institute, Miami, Florida, United States

An Open-label Study of Poly-l-lactic Acid for Correction of Wrinkles in the décolletage Area

Not Applicable
Completed
Conditions
Wrinkles in Decolletage
Interventions
Device: poly-l-lactic acid (Sculptra)
First Posted Date
2022-09-14
Last Posted Date
2024-08-20
Lead Sponsor
Galderma R&D
Target Recruit Count
30
Registration Number
NCT05538728
Locations
🇺🇸

Galderma Study Site, Solana Beach, California, United States

Sculptra Chart Review

Completed
Conditions
Non-facial Skin Aesthetic Conditions
Interventions
Device: Sculptra Aesthetic
First Posted Date
2022-07-19
Last Posted Date
2022-10-24
Lead Sponsor
Galderma R&D
Target Recruit Count
500
Registration Number
NCT05463978
Locations
🇺🇸

Site Coordinator, New York, New York, United States

🇺🇸

Galderma Research Site, New York, New York, United States

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Phase 3
Completed
Conditions
Moderate to Severe Glabellar Lines
Interventions
Biological: OnabotulinumtoxinA
Biological: QM1114-DP
Biological: Placebo
First Posted Date
2022-07-19
Last Posted Date
2023-10-12
Lead Sponsor
Galderma R&D
Target Recruit Count
605
Registration Number
NCT05463965
Locations
🇨🇳

Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

🇨🇳

Tianjin University General Hospital, Tianjin, China

🇨🇳

Peking University First Hospital, Beijing, China

and more 3 locations

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2022-06-06
Last Posted Date
2025-01-03
Lead Sponsor
Galderma R&D
Target Recruit Count
192
Registration Number
NCT05405985
Locations
🇺🇸

Galderma Investigational Site 7024, Tempe, Arizona, United States

🇺🇸

Galderma Investigational Site 7023, Lincoln, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath